Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGS-003 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1: AGS-003+sunitinib | EXPERIMENTAL | Single arm study AGS-003 plus sunitinib |
| Name | Type | Description |
|---|---|---|
| AGS-003 | BIOLOGICAL | Dendritic cell Immunotherapeutic |
| Sunitinib | DRUG | An approved drug for the treatment of RCC |
Inclusion Criteria: Male and female subjects ≥18 years of age with newly diagnosed advanced stage RCC will be eligible for inclusion in this study if all of the following criteria apply: 1. Newly diagnosed advanced stage RCC. 2. Eligible for unilateral nephrectomy or partial nephrectomy; OR, Has l...
AGS-003 is an investigational monoclonal antibody being studied for the treatment of Renal Cell Carcinoma, a type of kidney cancer. It is currently in Phase 2 clinical development and has not been approved by the FDA. The drug is being evaluated in combination with a marketed renal cell carcinoma treatment.
AGS-003 is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical research to evaluate the safety and biologic activity of this investigational therapy in patients with advanced kidney cancer.
AGS-003 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received FDA approval and is still being studied in clinical trials. One Phase 2 trial has been completed, and the drug is not currently in any active trials.
AGS-003 has been studied in one clinical trial with the identifier NCT00678119. This Phase 2 trial, titled 'Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment,' was completed and enrolled 25 participants.
AGS-003 is a distinct investigational monoclonal antibody being developed by cbdMD, Inc. for Renal Cell Carcinoma. It is not the same as any other product the company may offer, as it is a biologic drug candidate in clinical development, not a consumer product.